International Immunopharmacology, Journal Year: 2024, Volume and Issue: 141, P. 112967 - 112967
Published: Aug. 24, 2024
Language: Английский
International Immunopharmacology, Journal Year: 2024, Volume and Issue: 141, P. 112967 - 112967
Published: Aug. 24, 2024
Language: Английский
Journal of Periodontal Research, Journal Year: 2024, Volume and Issue: unknown
Published: July 23, 2024
Abstract Periodontitis is a multifactorial immune‐mediated disease exacerbated by dysregulated alveolar bone homeostasis. Timely intervention crucial for management to prevent tooth loss. To successfully manage periodontitis, it imperative understand the cellular and molecular mechanisms involved in its pathogenesis develop novel treatment modalities. Non‐surgical periodontal therapy (NSPT) such as subgingival instrumentation/debridement has been underlying strategy over past decades. However, new NSPT approaches that target key signaling pathways regulating homeostasis have shown positive clinical outcomes. This narrative review aims discuss endogenous impaired periodontitis highlight outcomes of preventive avoid invasive therapies. Although anti‐resorptive therapeutic adjuncts demonstrated beneficial outcomes, adverse events reported. Diverse immunomodulatory therapies targeting osteoblast/osteoclast (OB/OC) axis promising vivo. Future controlled randomized trials (RCT) would help clinicians patients selection preventing molecules effectively treat or periodontitis.
Language: Английский
Citations
2International Immunopharmacology, Journal Year: 2024, Volume and Issue: 141, P. 112967 - 112967
Published: Aug. 24, 2024
Language: Английский
Citations
1